Supreme LMA Use in Urgent Caesarean Section

July 31, 2020 updated by: Wei Yu Yao, QuanZhou Women and Children's Hospital

Supreme Laryngeal Mask Use in Urgent Caesarean Section

The Supreme Laryngeal Mask Airway (SLMA) is a single use supraglottic device that provides a good seal for positive pressure ventilation and good first attempt insertion rate of 98% in low risk patients undergoing elective Caesarean section. It has a double aperture design that facilitates the introduction of an orogastric tube to aspirate gastric contents.

The primary study hypothesis is the first attempt insertion success rate of SLMA use in urgent Caesarean section.

Study Overview

Status

Completed

Conditions

Detailed Description

Investigators propose a prospective cohort study to study the first attempt insertion success rate of supreme LMA in general anaesthesia for urgent caesarean section.

Study Type

Interventional

Enrollment (Actual)

584

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Fujian
      • Quanzhou, Fujian, China, 700
        • Quanzhou Women's and Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age 18 to 50 years old
  • American Society of Anesthesiology status 1 or 2
  • Weight 40 to 75kg
  • Normal airway assessment
  • Term pregnancy (36 weeks or more)
  • Urgent Caesarean Section

Exclusion Criteria:

  • Body mass index (35 or more)
  • Difficult airway (Mallampati 4 or abnormal airway assessment)
  • Gastrooesophageal reflux

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Supreme Laryngeal Mask Airway
Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
First attempt insertion success rate
Time Frame: 1 hour
An attempt is defined as insertion and withdrawal of the device from the patient's airway
1 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to effective airway placement
Time Frame: 1 hour
Interval from when the device was picked up until appearance of the first end-tidal carbon dioxide waveform
1 hour
Aspiration
Time Frame: 1 hour
Signs of aspiration as evidenced by perioperative hypoxaemia, wheezing or crepitations upon auscultation of lungs or postoperative dyspnoea with chest x ray signs of aspiration
1 hour
blood on SLMA on removal
Time Frame: 1 hour
inspection for presence of blood upon removal of SLMA
1 hour
Sore throat
Time Frame: 1 hour
Sore throat present in recovery room
1 hour
Regurgitation
Time Frame: 1 hour
Gastric contents identified in the mouth with pH less than 4
1 hour
Seal pressure
Time Frame: 1 hour
Recorded by closing the adjustable pressure limiting valve and insufflating the closed breathing system with 3L/min fresh gas flow. The peak circuit airway pressure achieved will be recorded.
1 hour
Gastric aspirate
Time Frame: 1 hour
Volume of gastric aspirate using gastric tube and pH of gastric aspirate using litmus paper
1 hour
Neonatal outcomes
Time Frame: 1 hour
Neonatal birthweight. APGAR score. Umbilical venous cord pH
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2013

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

May 1, 2015

Study Registration Dates

First Submitted

December 31, 2013

First Submitted That Met QC Criteria

December 31, 2013

First Posted (Estimate)

January 3, 2014

Study Record Updates

Last Update Posted (Actual)

August 3, 2020

Last Update Submitted That Met QC Criteria

July 31, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 2013-11-11

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Airway Morbidity

Clinical Trials on Supreme Laryngeal Mask Airway

Subscribe